DICE Therapeutics Inc (DICE)
US23345J1043 - Common Stock
Stifel cuts Morphic to hold, doesn't see it as near-term M&A target (MORF)
Stifel has downgraded Morphic (MORF) to hold, stating that it believes open-label data for its drug candidate MORF-057 is not enough to score a near-term takeover deal. Read more.
Lilly Completes Acquisition of DICE Therapeutics
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The...
Lilly Announces Extension of Tender Offer to Acquire DICE
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, QUOT, TALS, CFMS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages EMAN, NETI, PDCE, DICE, and NETI Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
IMPORTANT ALERT: Halper Sadeh LLC Investigates DICE, IMNM, AJX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies.
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review
But the major indexes and leading stocks generally showed healthy action.
Why Dice Therapeutics Stock Bolted Higher This Week
The small-cap drugmaker fetched a hefty premium in a buyout deal with Eli Lilly.
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?
The pharma giant's latest acquisition might be on the small side, but it could yield an important new growth driver in the years ahead.
Noteworthy Tuesday Option Activity: MSTR, DICE, IIPR
Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know
Lilly could get a couple of promising autoimmune-disease drugs with the transaction.
Moore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, DICE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Shares of Dice Therapeutics Are Skyrocketing Tuesday
The company received a buyout offer from Eli Lilly.
Shareholder Alert: Ademi LLP investigates whether DICE Therapeutics, Inc. has obtained a Fair Price in its transaction with Eli Lilly and Company
/PRNewswire/ -- Ademi LLP is investigating DICE (NASDAQ: DICE) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli...
PLTR Stock Alert: Why Raymond James Just Downgraded Palantir
Palantir (PLTR) stock is on the move Tuesday after Raymond James analysts downgraded the company's shares but increased its price target.
RIVN Stock Alert: Rivian Jumps on the Tesla Bandwagon for EV Charging
Rivian (RIVN) stock is in the news Tuesday as investors react to the electric vehicle (EV) company joining Tesla's (TSLA) charging standard.